P435 Real-world clinical outcomes after elective discontinuation of first-use biologics in IBD patients
ECCO'20 Vienna
2020
P436 Evaluation of targeted vitamin D supplementation regimen in postoperative patients with Crohn’s disease
ECCO'20 Vienna
2020
P438 Real-life effectiveness and safety of ABP501, an adalimumab biosimilar, in inflammatory bowel disease: a multicentre Italian study
ECCO'20 Vienna
2020
P439 Patient’ recruitment for a Phase 3 inflammatory bowel disease (IBD) programme is significantly increased when accessing the CT-SCOUT™ platform
ECCO'20 Vienna
2020
P440 Polimedication in patients with inflammatory bowel disease: prevalence and outcomes in a retrospective unicentric series
ECCO'20 Vienna
2020
P441 Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis
ECCO'20 Vienna
2020
P443 Magnetic resonance imaging after ligation of the intersphincteric fistula tract for high perianal fistulas in Crohn’s disease: a retrospective cohort study
ECCO'20 Vienna
2020
P444 The impact of azathioprine on inflammatory bowel disease patients’ overall health-related quality of life: a single-centre retrospective cohort study
ECCO'20 Vienna
2020
P446 Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study
ECCO'20 Vienna
2020
P447 No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy
ECCO'20 Vienna
2020
P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension
ECCO'20 Vienna
2020
P449 Systematic review with meta-analysis: risk of lymphoma associated with anti-tumour necrosis factor (TNF) agents in inflammatory bowel disease
ECCO'20 Vienna
2020
P451 Short-and long-term effectiveness of ustekinumab in patients with Crohn’s disease: real-world data from a German IBD cohort
ECCO'20 Vienna
2020